Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totaling 61,079 shares, an increase of 152.8% from the July 15th total of 24,157 shares. Based on an average daily trading volume, of 359,826 shares, the short-interest ratio is currently 0.2 days. Approximately 0.5% of the shares of the company are sold short.

Institutional Trading of Biofrontera

A hedge fund recently raised its position in Biofrontera stock. Geode Capital Management LLC boosted its stake in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the quarter. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 as of its most recent SEC filing. 10.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BFRI has been the subject of several analyst reports. Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of Biofrontera to a “hold” rating in a research report on Saturday, July 18th. Finally, Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Biofrontera Stock Performance

NASDAQ BFRI opened at $1.26 on Friday. The firm has a market cap of $16.13 million, a price-to-earnings ratio of -1.30 and a beta of 0.78. The company has a quick ratio of 1.09, a current ratio of 1.20 and a debt-to-equity ratio of 0.78. The business has a 50-day moving average price of $1.07 and a 200-day moving average price of $0.98. Biofrontera has a twelve month low of $0.55 and a twelve month high of $1.40.

Biofrontera (NASDAQ:BFRI) last issued its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative return on equity of 515.34% and a negative net margin of 25.66%.The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $9.50 million. As a group, equities research analysts predict that Biofrontera will post -0.3 EPS for the current fiscal year.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.